Enterome to Join 2024 Jefferies Global Healthcare Conference

PARIS, May 30, 2024 - Enterome, a company at the forefront of developing novel immunomodulatory drugs aimed at combating both solid and liquid malignancies as well as inflammatory diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The event is scheduled to take place at the Marriott Marquis in New York, NY, from June 4-6, 2024. The company will be represented by its co-founder and CEO, Pierre Bélichard, along with CFO Christelle Dumoussaud.

About Enterome

Enterome is a pioneering clinical-stage biopharmaceutical company working on groundbreaking drugs specifically designed to modulate the immune system for cancer and immune disease treatments. The company leverages its innovative Mimicry platform to delve into biological interactions occurring between millions of gut bacterial proteins and the human body. This platform enables them to discover and develop new therapeutic agents with unique properties.

The company's drug candidates are primarily small proteins and peptides that emulate the structure and functions of specific antigens, hormones, or cytokines, thereby modulating the immune system.

Product Pipeline

Enterome's drug development pipeline includes two primary categories: OncoMimics™ and EndoMimics™.

1. OncoMimics™

- EO2463: This peptide-based immunotherapy is currently in a Phase 2 clinical trial targeting indolent non-Hodgkin lymphomas. Initial results have shown a favorable safety profile along with promising early signs of efficacy.

- EO2401: This candidate has successfully wrapped up a Phase 2 clinical trial in glioblastoma patients. Enterome is actively seeking a pharmaceutical partner to advance EO2401 into a pivotal trial phase.

2. EndoMimics™

- The EndoMimics™ pipeline focuses on next-generation bioactive proteins that act like human hormones or cytokines. The company is collaborating with Nestlé Health Science to develop treatments for food allergies and inflammatory bowel disease (IBD).

Corporate Background

Enterome is headquartered in Paris, France, and employs a team of 70 dedicated professionals. Since its founding, the company has successfully raised €118 million in funding from a mix of European and US-based life science investors, alongside an additional €100 million through pharmaceutical partnerships.

Enterome's innovative research and development efforts continue to push the boundaries of immunotherapy, aiming to offer new hope and improved outcomes for patients battling cancer and immune diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!